We are live on ! Find out more
XBI icon

State Street SPDR S&P Biotech ETF

769 hedge funds and large institutions have $10.2B invested in State Street SPDR S&P Biotech ETF in 2024 Q3 according to their latest regulatory filings, with 88 funds opening new positions, 240 increasing their positions, 270 reducing their positions, and 73 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 73

17% more funds holding in top 10

Funds holding in top 10: 1821 (+3)

11% more capital invested

Capital invested by funds: $9.17B → $10.2B (+$994M)

1.23% more ownership

Funds ownership: 128.67%129.89% (+1.2%)

1% more funds holding

Funds holding: 761769 (+8)

11% less repeat investments, than reductions

Existing positions increased: 240 | Existing positions reduced: 270

16% less call options, than puts

Call options by funds: $2.8B | Put options by funds: $3.33B

Holders
769
Holders Change
+8
Holders Change %
+1.05%
% of All Funds
11.04%
Holding in Top 10
21
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+16.67%
% of All Funds
0.3%
New
88
Increased
240
Reduced
270
Closed
73
Calls
$2.8B
Puts
$3.33B
Net Calls
-$526M
Net Calls Change
+$836M
Name Holding Trade Value Shares
Change
Change in
Stake
MS
326
Maven Securities
Jersey
$994K -$7.57M -77,095 -88%
DMKJ
327
David M. Knott Jr
$988K -$393K -4,000 -29%
SIGI
328
Susquehanna International Group (Ireland)
Ireland
$988K
BPAMU
329
BTG Pactual Asset Management US
New York
$988K +$982K +9,997 New
MIM
330
Macroview Investment Management
Maryland
$954K -$41.3K -420 -4%
ICM
331
Ionic Capital Management
New York
$953K
VWA
332
Visionary Wealth Advisors
Illinois
$948K +$349K +3,557 +59%
SI
333
Shaker Investments
Ohio
$946K +$365K +3,720 +64%
TSW
334
Thompson Siegel & Walmsley
Virginia
$944K
AAS
335
Ameritas Advisory Services
Nebraska
$943K -$26.9K -274 -3%
AR
336
Advisory Research
Illinois
$939K -$31.5K -321 -3%
SF
337
Synovus Financial
Georgia
$928K +$485K +4,939 +111%
RIL
338
Rothschild Investment LLC
Illinois
$926K +$451K +4,595 +96%
PGFC
339
Peapack-Gladstone Financial Corp
New Jersey
$925K -$71.4K -727 -7%
BCA
340
Bray Capital Advisors
Florida
$925K -$54K -550 -6%
ASN
341
Advisory Services Network
Georgia
$918K
FHA
342
Flagship Harbor Advisors
Massachusetts
$914K -$19.3M -196,863 -96%
KWM
343
Koa Wealth Management
California
$911K -$84.6K -861 -9%
MC
344
Mathes Company
New York
$901K -$31.9K -325 -3%
IFWM
345
Institute for Wealth Management
Colorado
$894K +$31.9K +325 +4%
AI
346
Atria Investments
North Carolina
$891K +$18.5K +188 +2%
PFA
347
Petra Financial Advisors
Colorado
$890K +$14.9K +152 +2%
BFM
348
Boothbay Fund Management
New York
$886K +$388K +3,945 +79%
WAS
349
Wealth Advisory Solutions
Indiana
$883K +$62K +631 +8%
LA
350
LM Advisors
California
$873K -$1.49M -15,188 -63%

XBI Hedge Fund Activity: Q3 2024 in Review

769 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q3 2024, worth a combined $10.2B — up 11% from $9.17B a quarter earlier.

Buyers outnumbered sellers: 88 funds opened new XBI positions and 73 closed out — a net gain of 15 holders — while 240 added to existing stakes and 270 trimmed.

The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, adding an estimated $603M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $281M sold.

  • 769 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q3 2024, up from 761 in Q2 2024.
  • Funds reported $10.2B of State Street SPDR S&P Biotech ETF stock for Q3 2024, up 11% quarter-over-quarter.
  • 88 funds opened new State Street SPDR S&P Biotech ETF positions in Q3 2024 and 73 closed out, a net change of +15 holders.
  • The largest State Street SPDR S&P Biotech ETF buyer in Q3 2024 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $603M added.
  • The largest State Street SPDR S&P Biotech ETF seller in Q3 2024 was Avoro Capital Advisors, an estimated $281M sold.

Based on aggregated 13F filings for Q3 2024.